^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) + anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors
Published date:
11/09/2020
Excerpt:
Eligible pts received combination of KN026 and KN046...3 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks….KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors.
DOI:
10.1136/jitc-2020-SITC2020.0339
Trial ID:
Source:
Title:
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
Published date:
11/09/2020
Excerpt:
The objective response rate in pts with HER2-positive tumors (n = 14 efficacy evaluable pts) was 9/14 (64.3%, 95% CI 35.1~87.2%) and disease control rate 13/14 (92.9%, 95% CI 66.1~99.8%). 4 out of 5 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks. 4 out of 5 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks.
